Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 610-945-6 | CAS number: 53037-34-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity: Key study: The acute oral LD50 value of the test substance was >2000 mg/kg bw in female rats.
Acute dermal toxicity: The acute dermal LD50 value of the test substance was >2000 mg/kg bw in male and female rats.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- September 11, 2012 - December 12, 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld.- Age at study initiation: Young healthy adult rats, approximately 8-9 weeks old.- Weight at study initiation: 171 - 190 g.- Fasting period before study: The night before treatment the animals will be fasted. - Housing: 3 animals/cage.- Diet (e.g. ad libitum): Ad libitum.- Water (e.g. ad libitum): Ad libitum.- Acclimation period: 5-6 daysENVIRONMENTAL CONDITIONS- Temperature (°C): 19.9 – 24.1°C- Humidity (%): 30 - 52 %.- Air changes (per hr): 15-20 air exchanges/hour .- Photoperiod (hrs dark / hrs light): 12 hrs dark / 12 hrs light
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- (distilled)
- Details on oral exposure:
- VEHICLE:- Amount of vehicle (if gavage): 200 mg/mL- Lot/batch no. (if required): 3450611MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg bwDOSAGE PREPARATION (if unusual): The test item was freshly formulated at a concentration of 200 mg/mL in the vehicle. The formulation container was stirred continuously up to finishing the treatment. The purity factor was 2.18, therefore the dose to be adjusted was 2000 x 2.18 mg/kg bw prepared in distilled water at a dose volume of 10 ml/kg bw. With this the dose level was 2000 mg/kg bw referring to the dry component (46%) of the test item.CLASS METHOD (if applicable)- Rationale for the selection of the starting dose: In the lack of any preliminary toxicological information, 2000 mg/kg bw was selected to be the starting dose.
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 3 females rats per group (group 1 and confirmatory group 2).
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days.- Frequency of observations and weighing: Clinical observations were performed on all animals at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing and daily for 14 days thereafter. Body weight was measured on Days -1, 0 and 7 and Day 14 before necropsy.- Necropsy of survivors performed: Yes, all animals were subjected to a necropsy and a macroscopic examination.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Treatment did not cause mortality.
- Clinical signs:
- other: Treatment caused decreased activity, hunched back and piloerection.
- Gross pathology:
- Treatment was not associated with any test item related gross findings.
- Interpretation of results:
- not classified
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral LD50 value of the test substance was >2000 mg/kg bw in female rats.
- Executive summary:
The single-dose oral toxicity was performed according to OECD 423 Guideline and EU B.1tris Method (acute toxic class method) in female CRL: (WI) rats. Two groups (one confirmatory group) of three rats were exposed by single oral treatment to 2000 mg/kg bw. Mortality, clinical observations and body weight were analyzed for 14 days after exposure. In day 14, necropsy was performed and all animals were subjected to a necropsy and a macroscopic examination. No effects on mortality, body weight and macroscopic findings were observed. Treatment caused decreased activity, hunched back and piloerection. Under the conditions of this study, the acute oral LD50 was determined to be greater than 2000 mg/kg bw in female rats.
Reference
Dose level: 2000 mg/kg bw, Treatment on day 0. Sex: Female.
Cage No. | Animal number | Observations | Observation days | Frecuency | |||||||||||
0 | 1 | 2 | 3 | 4 | 5 | 6-14 | |||||||||
30’ | 1h | 2h | 3h | 4h | 6h | ||||||||||
1 | 8156 | Symptom Free | - | - | - | - | - | - | - | + | + | + | + | + | 13/20 |
Activity decreased | - | - | - | 1 | 1 | - | - | - | - | - | - | - | 2/20 | ||
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | + | + | + | + | + | - | - | - | - | - | 5/20 | ||
8157 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 | |
Activity decreased | - | - | - | 1 | 1 | - | - | - | - | - | - | - | 2/20 | ||
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | + | + | + | - | - | - | - | - | - | - | 3/20 | ||
8158 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 | |
Activity decreased | - | - | - | 1 | - | - | - | - | - | - | - | - | 1/20 | ||
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | + | + | + | - | - | - | - | - | - | - | 3/20 | ||
2 | 8159 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 |
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | - | + | + | - | - | - | - | - | - | - | 2/20 | ||
8160 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 | |
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | - | + | + | - | - | - | - | - | - | - | 2/20 | ||
8161 | Symptom Free | - | - | - | - | - | - | + | + | + | + | + | + | 14/20 | |
Hunched back | + | + | + | + | + | + | - | - | - | - | - | - | 6/20 | ||
Piloerection | - | - | - | + | + | - | - | - | - | - | - | - | 2/20 |
Remarks:
+ = present - = absent
h = hour (s) ‘ = minute
Frequency of observation = number of occurrence of observation / total number of observations
Severities: 1 = Slight/Small/Few; 2 = Moderate/Medium; 3 = Marked/Large/Many
Table 2. Body weight data.
Dose level: 2000 mg/kg bw, Treatment on day 0. Sex: Female.
Cage No. | Animal number | Body weight (g) Days | Body Weight Gain (g) | ||||||
-1 | 0 | 7 | 14 | -1 - 0 | 0 - 7 | 7 - 14 | -1 - 14 | ||
1 | 8156 | 191 | 181 | 203 | 224 | -10 | 22 | 21 | 33 |
8157 | 200 | 184 | 224 | 252 | -16 | 40 | 28 | 52 | |
8158 | 198 | 187 | 217 | 229 | -11 | 30 | 12 | 31 | |
2 | 8159 | 185 | 171 | 198 | 205 | -14 | 27 | 7 | 20 |
8160 | 195 | 189 | 218 | 226 | -6 | 29 | 8 | 31 | |
8161 | 199 | 190 | 221 | 238 | -9 | 31 | 17 | 39 | |
Mean: | 194.7 | 183.7 | 213.5 | 229.0 | -11.0 | 29.8 | 15.5 | 34.3 | |
Standard deviation: | 5.8 | 7.0 | 10.5 | 15.6 | 3.6 | 5.9 | 8.1 | 10.6 |
Table 3. Necropsy findings.
Dose level: 2000 mg/kg bw, Treatment on day 0. Sex: Female.
Cage No. | Animal number | Necropsy Day | External Observations | Internal Observations | Organ/Tisuue |
1 | 8156 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable |
8157 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable | |
8158 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable | |
2 | 8159 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable |
8160 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable | |
8161 | Day 14 | No external observations recorded | No internal observations recorded | Not applicable |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 001 mg/kg bw
- Quality of whole database:
- The study is a GLP compliant and has Klimisch score 1.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- September 12, 2012 - December 12, 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld.- Age at study initiation: Young adult rats.- Weight at study initiation: Males: 231-242 g, Females: 213-234 g- Housing: Individual caging.- Diet (e.g. ad libitum): Ad libitum.- Water (e.g. ad libitum): Ad libitum.- Acclimation period: 6 days.ENVIRONMENTAL CONDITIONS- Temperature (°C): 20.6 – 25°C.- Humidity (%): 30 - 54 %.- Air changes (per hr): 15-20 air exchanges/hour .- Photoperiod (hrs dark / hrs light): 12 hrs dark / 12 hrs light
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE- Area of exposure: back of the animals.- % coverage: 10% of the total body.- Type of wrap if used: Sterile gauze pads were placed on the skin to cover the test item. These gauze pads were kept in contact with the skin by a patch with adhesive hypoallergenic plaster. The entire trunk of the animal was then wrapped with semi occlusive plastic wrap for 24 hours.REMOVAL OF TEST SUBSTANCE- Washing (if done): The area of skin treated with the test item was washed with water of body temperature.- Time after start of exposure: 24 hoursTEST MATERIAL- Concentration: Purity factor of 2.18 to the dry content of the test item was used
- Duration of exposure:
- 24 hour
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5 animals/sex
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days- Frequency of observations and weighing: Clinical observations were performed on all animals at 1 and 5 hours after dosing and daily for 14 days thereafter. Body weight was measured prior to dosing on Day 0 and on Days 7 and 14. - Necropsy of survivors performed: Yes, gross macroscopic examination was performed on all animals at the end of the 2-week observation period (Day 14).
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Administration of the test item did not cause mortality.
- Clinical signs:
- other: No clinical signs were observed after treatment or during the 14 day observation period.
- Gross pathology:
- No macroscopic effects were observed at necropsy.
- Other findings:
- Local dermal signs: Multifocal erythema in different diameters from 2 – 4 mm was noted in 4/5 males and 3/5 females which was reversible within 72 hours. In case of one male, a wound covered with scab later was observed from Day 2 to Day 9. Yellow discoloration of the fur was observed at the outskirt of the exposed surface in 5/5 males and 5/5 females.
- Interpretation of results:
- not classified
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- The acute dermal LD50 value of the test substance was >2000 mg/kg bw in male and female rats.
- Executive summary:
The acute dermal toxicity of test substance was performed according to OECD 402 Guideline and EU B.3 Method in male and female rats. A limit test was carried out at 2000 mg/kg body weight (bw) in both sexes (5 rats/sex). The test item was applied under semi-occlusive conditions as supplied as a single dermal 24-hour exposure followed by a 14‑day observation period. No treatment related effects were observed on mortality, clinical signs, body weight and necropsy. Multifocal erythema in different diameters were noted which were reversible within 72 hours. In case of one male, a wound covered with scab later was observed from day 2 to 9. Yellow discoloration of the fur was observed at the outskirt of the exposed surface in all animals. The acute dermal median lethal dose (LD50) of the test substance was found to be higher than 2000 mg/kg bw in male and female rats.
Reference
Experimental results are included in the tables which contains the document attached ("Attached background material").
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 001 mg/kg bw
- Quality of whole database:
- The study is a GLP compliant and has Klimisch score 1.
Additional information
Acute oral toxicity: Key study: The single-dose oral toxicity was performed according to OECD 423 Guideline and EU B.1tris Method (acute toxic class method) in female CRL: (WI) rats. Under the conditions of this study, the acute oral LD50 was determined to be greater than 2000 mg/kg bw in female rats.
Acute dermal toxicity: Key study: The acute dermal toxicity was performed according to OECD 402 Guideline and EU B.3 Method in male and female rats. A limit test was carried out at 2000 mg/kg body weight (bw) in both sexes (5 rats/sex) under semi-occlusive conditions. The acute dermal median lethal dose (LD50) of the test substance was found to be higher than 2000 mg/kg bw in male and female rats.
Acute toxicity by inhalation: Data waiving (other justification): According to REACH Annex VIII, column 2: In addition to the oral route, for substances other than gases, the information mentioned under 8.5.2 to 8.5.3 shall be provided for at least one other route. The choice for the second route will depend on the nature of the substance and the likely route of human exposure. If there is only one route of exposure, information for only that route need be provided. The information is provided for dermal route.
Justification for selection of acute toxicity – oral endpoint
Only one study available.
Justification for selection of acute toxicity – dermal endpoint
Only one study available.
Justification for classification or non-classification
Oral acute toxicity LD50> 2000 mg/kg: not classified.
Dermal acute toxicity LD50> 2000 mg/kg: not classified.
Based on the available data, the substance is not classified for acute oral and dermal toxicity (LD50 > 2000 mg/kg bw) according to CLP Regulation no. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.